within Pharmacolibrary.Drugs.ATC.S;

model S02AA16
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.98,
    Cl             = 0.00023333333333333333,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.12,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S02AA16</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ofloxacin is a second-generation fluoroquinolone antibiotic used for the treatment of a variety of bacterial infections, including respiratory tract infections, urinary tract infections, skin infections, and certain types of ear and eye infections. It is approved for human use and is included in various national and international formularies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following single oral administration. Values reflect population mean estimates.</p><h4>References</h4><ol><li><p>Lamp, KC, et al., &amp; Rybak, MJ (1992). Ofloxacin clinical pharmacokinetics. <i>Clinical pharmacokinetics</i> 22(1) 32–46. DOI:<a href=\"https://doi.org/10.2165/00003088-199222010-00004\">10.2165/00003088-199222010-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1559306/\">https://pubmed.ncbi.nlm.nih.gov/1559306</a></p></li><li><p>Bethell, DB, et al., &amp; White, NJ (1996). Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. <i>Antimicrobial agents and chemotherapy</i> 40(9) 2167–2172. DOI:<a href=\"https://doi.org/10.1128/AAC.40.9.2167\">10.1128/AAC.40.9.2167</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8878600/\">https://pubmed.ncbi.nlm.nih.gov/8878600</a></p></li><li><p>Goa, KL, &amp; Noble, S (2003). Panipenem/betamipron. <i>Drugs</i> 63(9) 913–926. DOI:<a href=\"https://doi.org/10.2165/00003495-200363090-00005\">10.2165/00003495-200363090-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12678575/\">https://pubmed.ncbi.nlm.nih.gov/12678575</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S02AA16;
